Vir Biotechnology, Inc. VIR

VIR Company Overview

Vir Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing treatments and preventive therapies for serious infectious diseases and other high-burden conditions. The company operates primarily in the biotechnology and biopharmaceutical industries, with a strategy centered on leveraging immunologic insights to develop monoclonal antibodies, T-cell–based therapies, vaccines, and other immune-mediated technologies. Vir’s principal areas of focus have included hepatitis delta virus (HDV), chronic hepatitis B virus (HBV), influenza, HIV, and pandemic preparedness initiatives. The company generates revenue primarily through collaboration agreements, licensing arrangements, and research partnerships, while its product portfolio remains largely in clinical development stages.

Vir was founded in 2016 by biotechnology investor and entrepreneur Robert Nelsen and immunologist Herbert “Skip” Virgin. Since inception, the company has expanded through acquisitions, licensing transactions, and strategic collaborations with major pharmaceutical and biotechnology companies. Vir became widely recognized during the COVID-19 pandemic through its collaboration with GlaxoSmithKline on sotrovimab, a monoclonal antibody developed for SARS‑CoV‑2. The company’s positioning has emphasized integrating immunology expertise with advanced platform technologies and partnerships to address infectious diseases with significant unmet medical need.